rabbit Anti-c-Jun, NT (Transcription Factor AP-1, Activator Protein 1, AP1, Proto-oncogene c-Jun, V-jun Avian Sarcoma Virus 17 Oncogene Homolog, p39, JUN) Monoclonal Antibody [Clone:60A8]

rabbit Anti-c-Jun, NT (Transcription Factor AP-1, Activator Protein 1, AP1, Proto-oncogene c-Jun, V-jun Avian Sarcoma Virus 17 Oncogene Homolog, p39, JUN) Monoclonal Antibody [Clone:60A8]

Référence 376930-300ul

Conditionnement : 300ul

Marque : US Biological

Contactez votre distributeur local :


Téléphone : +1 850 650 7790


376930 c-Jun, NT (Transcription Factor AP-1, Activator Protein 1, AP1, Proto-oncogene c-Jun, V-jun Avian Sarcoma Virus 17 Oncogene Homolog, p39, JUN)

Clone Type
Monoclonal
Host
rabbit
Source
human
Swiss Prot
P05412
Isotype
IgG
Grade
Purified
Applications
ChIP IF IHC IP WB
Crossreactivity
Hu Mk Mo Rt
Shipping Temp
Blue Ice
Storage Temp
-20°C

c-Jun is a member of the Jun Family composed of c-Jun, JunB and JunD, and is a component of the transcription factor AP-1. AP-1 is composed dimers of Fos, Jun and ATF family members, and binds and activates transcription at TRE/AP-1 elements (Reviewed in 1). Extracellular signals including growth factors, chemokines and extracellualar stress activate AP-1-dependent transcription. The transcriptional activity of c-Jun is regulated by phosphorylation at Ser63 and Ser73 through SAPK/JNK (reviewed in 2). Knock-out studies in mice have shown that c-Jun is essential for embryogenesis (3), and subsequent studies have demonstrated roles for c-Jun in various tissues and developmental processes including axon regeneration (4), liver regeneration (5) and T cell development (6). AP-1 regulated genes exert diverse biological functions including cell proliferation, differentiation, and apoptosis, as well as transformation, invasion and metastasis, depending on cell type and the context of the cell (7-9 ). Other target genes regulate survival as well as hypoxia and angiogenesis (8,10). c-Jun has emerged as promising therapeutic target for cancer, vascular remodeling, acute inflammation, as well as rheumatoid arthritis (11-13).

Applications: 
Suitable for use in Western Blot, Immunoprecipitation, Immunohistochemistry, Immunofluorescence and ChIP. Other applications not tested.

Recommended Dilution:
Western Blot: 1:1000, incubate membrane with diluted antibody in 5% BSA, 1X TBS, 0.1% Tween-20 at 4°C with gentle shaking, overnight.
Immunoprecipitation: 1:50
Immunohistochemistry (Paraffin): 1:400
Immunohistochemistry (Frozen): 1:400
Immunofluorescence (IF-IC): 1:50
ChIP: 1:50
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Applications
Product Type: Mab|Isotype: IgG|Clone No: 60A8|Host: rabbit|Source: human|Concentration: Not Determined |Form: Supplied as a liquid in 10mM sodium HEPES, pH 7.5, 150mM sodium chloride, 0.1mg/ml BSA, 0.02% sodium azide, 50% glycerol.|Purity: Purified|Immunogen: GST-protein corresponding to the N-terminal sequence of human c-Jun.|Specificity: Recognizes endogenous levels of total human c-Jun protein, regardless of phosphorylation state. Species Crossreactivity: mouse, rat and monkey.||Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Immunogen
GST-protein corresponding to the N-terminal sequence of human c-Jun.
Form
Supplied as a liquid in 10mM sodium HEPES, pH 7.5, 150mM sodium chloride, 0.1mg/ml BSA, 0.02% sodium azide, 50% glycerol.
Purity
Purified
Specificity
Recognizes endogenous levels of total human c-Jun protein, regardless of phosphorylation state. Species Crossreactivity: mouse, rat and monkey.
References
1. Jochum, W. et al. (2001) Oncogene 20, 2401–12. |2. Davis, R.J. (2000) Cell 103, 239–52.|3. Hilberg, F. et al. (1993) Nature 365, 179–81.|4. Raivich, G. et al. (2004) Neuron 43, 57–67.|5. Behrens, A. et al. (2002) EMBO J 21, 1782–90.|6. Riera-Sans, L. and Behrens, A. (2007) J Immunol 178,|5690–700.|7. Leppä, S. and Bohmann, D. (1999) Oncogene 18, 6158–62.|8 Shaulian, E. and Karin, M. (2002) Nat Cell Biol 4, E131–6.|9 Weiss, C. and Bohmann, D. (2004) Cell Cycle 3, 111–3.|10 Karamouzis, M.V. et al. (2007) Mol Cancer Res 5, 109–20.|11. Kim, S. and Iwao, H. (2003) J Pharmacol Sci 91, 177–81.|12. Weiss, C. and Bohmann, D. (2004) Cell Cycle 3, 111–3.|13. Dass, C.R. and Choong, P.F. (2008) Pharmazie 63, 411–4.